Ixabepilone, a novel epothilone analog in the treatment of breast cancer.

Date publication

avril 2008

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BORG Christophe , Dr CHAIGNEAU Loïc , Pr PIVOT Xavier , Dr DEMARCHI Martin

Tous les auteurs :
Pivot X, Villanueva C, Chaigneau L, Nguyen T, Demarchi M, Maurina T, Stein U, Borg C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/18363523

Résumé

BACKGROUND: Natural epothilones and their analogs promote tumor cell death by binding to tubulin and stabilizing microtubules, causing cell death. Ixabepilone (BMS-247550, Ixempra) is an epothilone analog that optimizes the properties naturally observed with epothilone B. OBJECTIVE: To provide an overview of the results achieved by ixabepilone in metastatic breast cancer. METHODS: A PubMed search was performed to provide an extensive review of all published data on ixabepilone, in addition to all data reported from international congresses, from 2003 to 2007. RESULTS/CONCLUSION: There is a clear need for new agents active against resistant metastatic breast cancer and ixabepilone might be a welcome new compound in this situation.

Référence

Expert Opin Investig Drugs. 2008 Apr;17(4):593-9.